Researchers reported macropinocytosis-mediated recyclable LYTACs (McR-TACs), a targeted protein-degradation approach designed to address limitations of earlier LYTAC systems that rely on receptor-dependent, nonrecyclable trafficking. The platform uses a recyclable chimera intended to enter cells via macropinocytosis in a receptor-independent manner, then dissociates in acidic endocytic compartments for repeated degradation cycles. In preclinical mouse models, the degraders induced durable degradation of programmed death ligand 1 (PD-L1) and macrophage migration inhibitory factor, both linked to tumor immune evasion and inflammatory signaling. The report frames the work as an expansion of extracellular targeted degradation capabilities. For drug discovery teams, the emphasis on recyclability and receptor independence positions McR-TACs as a potential differentiator in next-generation targeted degradation modalities.